Pink SheetUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
In VivoPharma’s AI moment has arrived—not as a futuristic vision, but as a pragmatic engine of operational and scientific change. To understand how biopharma companies are navigating this shift, Define Ventu
ScripUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
Generics BulletinRoche is anticipating biosimilar competition to both Perjeta (pertuzumab) and Xolair (omalizumab) by the end of 2026, marking a newly defined horizon for loss of exclusivity – especially for Perjeta,